Key Highlights

  • Amdocs (NASDAQ:DOX) was down 40.12% to USD 37.38 after fiscal 2027 guidance pointed to reported Revenue down 14.3% to 17.9%.
  • Skyworks Solutions (NASDAQ:SWKS) was down 16.28% to USD 71.50 after fiscal fourth quarter revenue fell 5% to USD 1,045.7 million.
  • Crexendo (NASDAQ:CXDO) was down 12.67% to USD 5.03 even though third quarter revenue rose 44% to USD 25.2 million.
  • RxSight (NASDAQ:RXST) was down 9.59% to USD 4.15 after third quarter revenue dropped 19% to USD 24.6 million.
  • USANA Health Sciences (NYSE:USNA) was down 9.21% to USD 13.50 after cutting its fiscal 2026 outlook.

Amdocs (NASDAQ:DOX) (down USD 25.04, 40.12%): Guidance Shock and a Dispute With Its Largest Customer

Amdocs (NASDAQ:DOX) was down 40.12% to USD 37.38 in pre-market trading on November 4, 2026, a fall of USD 25.04 from the November 3, 2026 close. The catalyst was fiscal 2026 results published on November 3, 2026, where the outlook mattered more than the quarter. Quarterly revenue of USD 1.194 billion rose 3.8%, but fiscal 2027 reported revenue is guided to decline 14.3% to 17.9%.

Management tied most of the weakness to T-Mobile (NASDAQ:TMUS), its largest customer, citing reduced discretionary spending, the integration of UScellular customers and a contract dispute. Each side has alleged material breach, and the guidance allows for a scenario in which the agreements are terminated. Non-GAAP diluted EPS is guided down 26% to 30%. The key risk is the arbitration outcome.

Skyworks Solutions (NASDAQ:SWKS) (down USD 13.90, 16.28%): Soft December Quarter Outlook After the Qorvo Combination

Skyworks Solutions (NASDAQ:SWKS) was down 16.28% to USD 71.50 in pre-market trading on November 4, 2026, following its fiscal fourth quarter release issued after the close on November 3, 2026. Revenue was USD 1,045.7 million, down 5% from USD 1,100.2 million.

For the December quarter, the company guided combined revenue of USD 1.80 billion to USD 1.90 billion and expects smartphone revenue to fall by a low-teens percentage sequentially. Debt rose to USD 2,472.8 million from USD 995.8 million. Integration execution and smartphone Demand are the main risks, as the company targets USD 500 million or more of annual cost synergies within 24 to 36 months of closing.

USANA Health Sciences (NYSE:USNA) (down USD 1.37, 9.21%): Core Customer Decline and a Reduced Outlook

USANA Health Sciences (NYSE:USNA) was down 9.21% to USD 13.50 in pre-market trading on November 4, 2026. The catalyst was the third quarter 2026 Earnings release of November 3, 2026, which showed net sales down 3.6% to USD 205.9 million. Core Nutritional active customers fell 8% to 356,000 from 388,000.

The company now expects fiscal 2026 net sales approaching USD 900 million, from USD 910 million before, and adjusted diluted EPS of USD 0.55, down from USD 0.76. Cash was USD 178.9 million with no debt outstanding. A risk is the shrinking core customer base and a second quarter adjusted EBITDA correction.

Crexendo (NASDAQ:CXDO) (down USD 0.7298, 12.67%): Revenue Growth Meets a Profit Squeeze

Crexendo (NASDAQ:CXDO) was down 12.67% to USD 5.03 in pre-market trading on November 4, 2026, after third quarter results released on November 3, 2026. Total revenue rose 44% to USD 25.2 million from USD 17.5 million, yet GAAP Net Income slipped to USD 1.1 million, or USD 0.03 per share, from USD 1.5 million, or USD 0.05.

Operating expenses rose 49% to USD 24.1 million, outpacing revenue growth, and the release carried no guidance. Cash was USD 22.8 million at September 30, 2026, down from USD 31.4 million at year end 2025, and the main risks are Acquisition integration and rising costs relative to GAAP profit.

RxSight (NASDAQ:RXST) (down USD 0.4402, 9.59%): A 19% Revenue Drop and a Wider Loss

RxSight (NASDAQ:RXST) was down 9.59% to USD 4.15 in pre-market trading on November 4, 2026, after third quarter 2026 results released after the regular session on November 3, 2026. Revenue fell 19% to USD 24.6 million from USD 30.3 million, and net loss widened to USD 16.2 million, or USD 0.39 per share.

Management cited seasonality, competition and disruption from a near doubling of the sales organization, and expects fourth quarter lens sales to rise mid to high single digits sequentially. Cash and short-term investments were USD 254.7 million. As a Penny Stock trading below USD 5, shares can be highly volatile with limited liquidity, and any future Equity raise could dilute holders.

Where Things Stand

The five stocks fell for different reasons: Amdocs (NASDAQ:DOX) on a guidance reset, Skyworks Solutions (NASDAQ:SWKS) on a soft combined outlook, USANA Health Sciences (NYSE:USNA) on a lowered forecast, Crexendo (NASDAQ:CXDO) on thinner GAAP profit, and RxSight (NASDAQ:RXST) on falling revenue. Items to watch include the T-Mobile dispute, the first combined Skyworks quarter, USANA Hiya trends and RxSight lens volume. Pre-market moves can reverse once the regular session opens.